Maryland State Retirement & Pension System Sells 4,969 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Maryland State Retirement & Pension System lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 13.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,706 shares of the biopharmaceutical company’s stock after selling 4,969 shares during the period. Maryland State Retirement & Pension System’s holdings in Catalyst Pharmaceuticals were worth $793,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in CPRX. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth about $29,000. Sound Income Strategies LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth about $64,000. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 579 shares during the last quarter. Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $104,000. Finally, New Vernon Capital Holdings II LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $122,000. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In related news, insider Preethi Sundaram sold 2,324 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares in the company, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $20.34 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.00 and a 52 week high of $26.58. The stock has a market capitalization of $2.49 billion, a P/E ratio of 12.33, a PEG ratio of 0.80 and a beta of 0.70. The stock has a 50-day simple moving average of $22.07 and a 200 day simple moving average of $22.75.

Analysts Set New Price Targets

A number of analysts recently issued reports on CPRX shares. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $33.20.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.